We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Com tudo isso, será que o Velho Continente está preparado para Donald Trump ou foi pego cochilando na direção (de novo)? Uma tonelada de cocaína, três brasileiros inocentes e a busca por um ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

O novo diretor executivo do SNS tem um doutoramento em Economia pela London School of Economics and Science e é professor associado na Faculdade de Economia da Universidade do Porto. Nas autárquicas ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on Friday ...

Novo Nordisk (NYSE:NVO) is a Denmark-based firm that owns drug brands such as Levemir, Tresiba, NovoLog, Novolin R, and Novolin N. Overall, NVO ranks 6th on our list of firms that took a hit on ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Lone Star Funds is selecting advisers to explore a possible sale or initial public offering of Portuguese lender Novo Banco SA, according to people familiar with the matter. The private equity ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. In the phase 3b ...